ImmunoGen Message Board - Msg: 28678820

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	1/22/2013 12:01:48 AM
	Read Replies (1) of 5665

Frankly on Friday I was amazed that PATH's drug approval produced some volatility in the stock price, lots of volume, but at the end of the day, it was down a penny. While I still believe IMGN should be up somewhat on the news of approval, I'm starting to believe it won't be as much as I've previously thought, because the Street generally believes it will happen. It may take awhile for sales data to start coming in routinely, but I believe we'll see growth in every quarter for years, and that's going to prove exciting as IMGN's royalties just keep moving up perhaps to nearly half a billion dollars in just a few years. Those sort of numbers will almost certainly bring all new high's and perhaps triple digits. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next